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Abstract
Introduction: COPD patients may be at increased risk for vitamin D (25(OH)D) deficiency, but risk factors for deficiency
among COPD patients have not been extensively reported.
Methods: Serum 25(OH)D levels were measured by liquid chromatography double mass spectrometry in subjects aged 40–
76 years from Western Norway, including 433 COPD patients (GOLD stage II-IV) and 325 controls. Levels ,20 ng/mL defined
deficiency. Season, sex, age, body mass index (BMI), smoking, GOLD stage, exacerbation frequency, arterial oxygen tension
(PaO2), respiratory symptoms, depression (CES-D score$16), comorbidities (Charlson score), treatment for osteoporosis, use
of inhaled steroids, and total white blood count were examined for associations with 25(OH)D in both linear and logistic
regression models.
Results: COPD patients had an increased risk for vitamin D deficiency compared to controls after adjustment for seasonality,
age, smoking and BMI. Variables associated with lower 25(OH)D levels in COPD patients were obesity ( =26.63), current
smoking ( =24.02), GOLD stage III- IV ( =24.71, =25.64), and depression ( =23.29). Summertime decreased the risk of
vitamin D deficiency (OR= 0.22).
Conclusion: COPD was associated with an increased risk of vitamin D deficiency, and important disease characteristics were
significantly related to 25(OH)D levels.
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Introduction
The role of vitamin D in preserving skeletal integrity is well
known. However, it has become increasingly clear that vitamin D
deficiency is associated with increased risk of chronic diseases like
cancer, autoimmune diseases, infectious diseases and cardiovas-
cular diseases [1]. There are substantial differences in the
prevalence of vitamin D deficiency in various populations; only
parts of this variation may be explained by different assays or
definition of lower reference limit [2,3].
Vitamin D deficiency may be a risk factor for respiratory
disease. In a report on subjects from a general population in the
United States, lower levels of vitamin D were associated with a
reduced level of lung function measured by forced expiratory
volume in one second (FEV1) and forced vital capacity (FVC) [4].
In addition, vitamin D deficiency has been implicated in the risk
for developing respiratory infections [5,6], and increasing
asthmatic symptoms or asthma in childhood [7,8].
Recent studies show that a substantial proportion of patients
with chronic obstructive pulmonary disease have deficient vitamin
D levels (,20 ng/mL) [9,10]. In one study of 262 COPD patients
from Belgium, FEV1, alveolar ventilation (KCO) in percent
predicted, body mass index (BMI), season of blood sampling and
gene variants in the vitamin D binding gene were found to be
significantly associated with 25(OH)D levels [9]. However,
whether COPD patients actually have a higher prevalence of
vitamin D deficiency than the general population is not yet well
documented.
In addition, few studies [11] have examined the association
between levels of vitamin D and other characteristics of COPD
than FEV1 such as exacerbation frequency, hypoxemia, comor-
bidities, and respiratory symptoms. The aim of the current study
was to compare levels of vitamin D in COPD patients and
healthy controls in a Norwegian population, and to further
evaluate the associations between important COPD characteris-
tics to levels of 25(OH)D, including the variables exacerbation
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frequency, hypoxemia, comorbidities, respiratory symptoms and
body mass index.
Methods
Ethics Statement
Written information was provided and written consent was
obtained prior to inclusion. The regional ethical committee
approved the study (Regional committee for medical and health
research ethics, Western Norway).
Study Population
All subjects were recruited from the same geographical area in
Western Norway, and participated in the baseline survey of the
Bergen COPD cohort Study from 2006 to 2009 at Haukeland
University Hospital. The study sample included 433 COPD
patients and 325 subjects without COPD, all Caucasians aged 40–
76 years.
Causes for exclusion for all subjects were known autoimmune
diseases or any active cancer in the last 5 years, but subjects with
common comorbidities (including cardiovascular disease and
diabetes) were not excluded. A smoking history of $10 pack-
years and a FEV1/FVC ratio ,0.7 and FEV1,80% predicted
were criteria for inclusion. A more detailed description of the
recruitment of participants and inclusion/exclusion criteria was
previously reported [12].
Data Sampling
A study physician examined all subjects and performed a
structured interview. Briefly, respiratory symptoms including
cough with phlegm and dyspnea were reported through a self-
completed questionnaire [12]. Information on smoking habits,
comorbidities, medication use, and exacerbations was obtained by
the study physician. Frequent exacerbations were defined as
having $2 exacerbations treated with antibiotics and/or oral
steroids and/or hospitalization the last 12 months. Arterial blood
gases were analysed for arterial oxygen on a Radiometer ABL 520
(Radiometer, Copenhagen, Denmark) within 5 min after sampling
by the study physician [13]. An arterial partial oxygen pressure of
,8.0 kPa defined hypoxemia. Pulmonary function was measured
both pre-and post-inhalation of 0.4 mg salbutamol, on a Viasys
Masterscope (Viasys, Hoechberg, Germany) by trained study staff.
Body mass index (BMI) was calculated as the weight (kg) divided
by the square of height (m2), and was categorized as underweight
(BMI ,18.5), normal (BMI 18.5–24.99), overweight (BMI 25.0–
29.99), and obese (BMI 30.0 or more) according to the current
World Health Organization (WHO) classification. Comorbidities
were categorized using the Charlson Comorbidity Index (CCI)
[14]. Depressive symptomatology was measured using the Centre
for Epidemiologic Studies Depression Scale (CES-D), where a
positive score of 16 or more defined depression [15]. Season was
defined as winter (December-March), spring (April-May), summer
(June-September), and autumn (October-November).
The study design and data collection has been described in
more detail previously [12].
Laboratory Measurements
Peripheral venous blood was drawn at the baseline visit, and
coagulated at room temperature for 30–45 min, followed by
centrifugation at 25006g (15 min 4uC). All serum samples were
stored at $70uC and thawed immediately before analysis.
Measurement of individual 25(OH)D3 and 25(OH)D2 levels was
performed at the Hormone Laboratory at Haukeland University
Hospital using an in-house developed liquid chromatography
double mass spectrometry (LC-MS/MS) method [16]. The LC-
MS/MS method allowed full distinction between 25(OH)D3 and
25(OH)D2. The within-day precision (CV) was #3.1%, and the
between-day precision (CV) was #8.7. Only seven individuals had
detectible levels of 25(OH)D2. Total 25(OH)D was defined as the
sum of 25(OH)D2 and 25(OH)D3.
Statistical Analyses
Serum concentrations of 25(OH)D were normally distributed.
Differences in mean 25(OH)D by bivariate predictors were
examined with parametrical tests. We analysed the relation
between study category and levels of 25(OH)D both by linear
and logistic regression after adjusting for possible confounders:
Season, sex, age, BMI, smoking, and comorbidities. A cut off level
for vitamin D deficiency were defined as ,20 ng/mL [1] for the
logistic model. When building the regression models for the levels
of vitamin D among COPD patients only, a backward stepwise
method was used for both the linear and logistic models. The
following variables were included from the start: Age, sex, BMI,
disease severity staged accordingly to the global initiative of
chronic obstructive lung disease (GOLD), hypoxemia, dyspnea
grade III, use of inhaled steroids, comorbidity (Charlson score ,2
or$2), total white blood cell count, treatment for osteoporosis (yes
or no), exacerbation frequency, and CES-D score. Variables
remained in the model if their significance level were less than
0.10. After the first run, all excluded variables were reintroduced
one at a time and retained in the final model if their significance
level were less than 0.10.
A p-value of ,0.05 was assumed to indicate statistical
significance of observed associations. All analyses were computed
with Stata version 10.1 (StataCorp. LP, College Station, TX,
USA).
Results
The characteristics of the study population are shown in
Table 1. There were more men than women, both among COPD
patients and controls. Difference in mean age between the groups
was 4.9 years, with a higher mean in COPD patients (63.5 years).
The COPD patients had more comorbidities and 21% had
depression as defined by the CES-D score, compared to 6% of the
controls. Only one subject was underweighted in the control group
(0.5%), versus 8% in the COPD group.
Among COPD patients, 9% had $2 exacerbations last year,
69% used inhaled steroids, and overall mean FEV1 in percent
predicted was 49% (Table 1).
Factors Associated with 25(OH)D in COPD Patients and
Controls - Bivariate Analyses
Concentrations of 25(OH)D among COPD patients and
controls for different explanatory variables are shown in Table 2.
Unadjusted, there was no significant difference in serum levels of
25(OH)D between COPD patients and controls.
Current smoking and non-summer season were associated with
lower levels of serum 25(OH)D in both groups. The importance of
season for the measured levels of 25(OH)D is shown in Figure 1.
Among the controls, lower age was associated with lower levels
of serum 25(OH)D (Table 2). Among the COPD patients, obesity
and underweight, higher GOLD stage, reporting dyspnea,
depression, or use of inhaled steroids, were all factors associated
with significantly lower levels of serum 25(OH)D (Table 2).
Bivariate associations between the continuous variables age,
FEV1, PaO2, and total white blood count with serum levels of
25(OH)D are shown in Table 3. Among the COPD patients, lower
COPD and Levels of Vitamin D
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FEV1 and lower PaO2, were associated with lower levels of
25(OH)D (Table 3). The significant correlation between FEV1 and
25(OH)D is presented in Figure 2.
Difference in Estimated Risk for Vitamin D Deficiency:
COPD vs. Controls
COPD status was associated with lower levels of 25(OH)D
( =24.34, p,0.001) and a more than doubled risk of being
categorised as deficient (OR=2.32, p= 0.001), after adjustment
for sex, age, BMI, smoking, comorbidities and season (Table 4).
Factors Associated with 25(OH)D in COPD Patients -
Multivariate Analyses
After adjustment, GOLD stage, obesity, smoking, and season
remained associated with both mean levels of 25(OH)D and total
deficiency (Table 5). Higher GOLD stage was associated both with
lower mean levels of 25(OH)D and increased risk for deficiency. In
summertime compared to wintertime, mean levels were higher
and the risk of deficiency was lower. Current smokers had lower
levels of 25(OH)D, and the risk of deficiency was significantly
higher. Patients with obesity had lower 25(OH)D levels and a
significantly increased risk for deficiency.
Depression was associated with lower levels of vitamin D
(Table 5), but only in the linear regression model. Although
hypoxemia and dyspnea were related to 25(OH)D in the bivariate
analyses, these relationships were not statistically significant in the
multivariate analyses.
Discussion
The prevalence of vitamin D deficiency was high in both COPD
patients and controls. When correcting for season, age, smoking,
comorbidities, and BMI, the estimated risk for vitamin D deficiency
was shown to be higher in COPD patients compared to controls. In
COPD patients, there was a significant association between vitamin
D levels and FEV1 in percent predicted, whereas hypoxemia and
exacerbation frequency the last year were not associated with
vitamin D levels. Previous studies have described vitamin D
deficiency as a common phenomenon in elderly populations [2,3].
In line with these observations, also in our study population we
observed a high prevalence of vitamin D deficiency; 34% in the
controls and 20%, 43% and 55% in the patients with GOLD stage
II-IV respectively. Although these are high numbers, the prevalence
was lower than what has been reported in two previous studies
[9,10]. A possible explanation for this difference could be a high
year-around consumption of fish and cod liver oil in Norway, which
naturally contains 25(OH)D3. Another explanation could be
differences between study samples in regard to COPD severity.
Season was a strong predictor of 25(OH)D levels, and relatively
more patients than controls were examined during summer in our
study sample. After adjustment for season, the real difference in
risk for vitamin D deficiency between COPD patients and healthy
controls became apparent. There are several potential explana-
tions for the increased risk for vitamin D deficiency in COPD
patients. The COPD patients have physical impairments leading
to inactivity and less time spent outdoors. Current smoking is a
known risk factor for vitamin D deficiency [17], but smoking was
adjusted for in the multivariable analyses. However, COPD
patients may have accelerated skin ageing due to smoking, renal
dysfunction, less fat tissue due to wasting, and treatment with
glucocorticoids, all factors that can affect vitamin D synthesis,
storage or catabolism [1].
In the NHANES III study, Black et al. found a dose- response
relationship between 25(OH)D and both FEV1 and FVC, but no
Table 1. Baseline characteristics of the study sample,
presented as mean6sd for continuous and percentage for
categorical variables.
COPD Controls p**
Subjects, n 433 325
Sex, % females 40 46 0.11
Age, years 63.566.9 58.669.8 ,0.001
Smoking habits: ,0.001
Never 0 14
Ex 56 32
Current 44 54
BMI1 (kg/m2) ,0.001
,18.5 8 0.5
18.5–24.9 43 39
25–30 35 45.5
.30 14 16
Comorbidity, Charlsons score ,0.001
0 0 70
1 58 22
2 23 6
3 12 2
4 7 0
Depression, CES-D score$16 ,0.001
Yes 21 6
Season# ,0.001
Winter 16 31
Spring 21 41
Summer 56 2
Autumn 7 26
FEV1 in percent predicted* 49614 102610 ,0.001
GOLD status:
II (FEV1 50–80) 46
III (FEV1 30–50) 42
IV (FEV1 0–30) 12
Resting PaO2
11 9.361.2
Hypoxemia, % yes 12
Symptoms, % yes
Cough with phlegm 59
Dyspnea (grade III) 44
Inhaled steroids, ICS, % yes 69
Exacerbations##:
,2 last 12 months 83
$2 last 12 months 17
Total white blood count 8.162.2
Vitamin D, 25(OH)D 0.86
,20 ng/mL 33 34
$20 ng/mL 67 66
1BMI: body mass index.
*FEV1: Forced expiratory volume in 1 s.
##Season was defined as winter (December-March), spring (April-May), summer
(June-September), and autumn (October–November).
#Exacerbations requiring either hospitalisation or treatment with oral
antibiotics or oral steroids.
11PaO2: arterial oxygen tension.
**Associations were tested with t-test and Chi-square.
doi:10.1371/journal.pone.0038934.t001
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correlation with airway obstruction defined as a change in FEV1/
FVC ratio [4]. However, in a recent study on COPD patients by
Janssens et al. [9], a strong relationship was found between GOLD
stage and vitamin D deficiency suggesting a relationship with
airway obstruction. A similar association between 25(OH)D and
FEV1 has been reported in adults with asthma [18]. Our study,
which included more COPD patients and where we adjusted for
potential confounders not assessed by Janssens et al., shows a
nearly identical relationship between airways obstruction and
vitamin D levels. Together these studies provide strong evidence
for this relationship, although the causality of this association
remains to be established.
What are the possible factors that may explain the association
between lung function and vitamin D levels? Several extra-renal
sites, including cells of the adaptive immune system, express the
vitamin D receptor and the enzyme, 1-hydroxylase, which converts
circulating 25(OH)D into the biologically active form 1,25(OH)2D
[1]. Both the innate and adaptive immune systems have been
implicated as important elements in the pathogenesis of COPD[19].
Interestingly, vitamin D has been shown to be an important
regulator of both elements of the immune system. Vitamin D has
been shown to affect dendritic cell maturation [20], T-cell activation
and proliferation [21], and Th1 T-cell development [22]. In
addition, vitamin D deficiency has been shown to be associated with
increased susceptibility to respiratory infections [5,6], which may in
part be explained by the ability of 1,25(OH)2D to increase
expression of antimicrobial peptides [23], and to decrease the
expression of pro-inflammatory cytokines and chemokines by e. g.
airway epithelial cells [24]. Thus, low local 1,25(OH) 2D levels could
potentially contribute to inflammation and susceptibility to infec-
tions, which may lead to an increased rate of FEV1 decline [25]. In
addition to its effects on immunity and inflammation, vitaminD also
has been shown to directly affect processes involved in tissue
remodelling such as fibroblast proliferation and collagen synthesis
[26], and modulation of matrix metalloproteinase (MMP) levels
[27]. Moreover, undiagnosed osteoporosis leading to vertebral
compressions may lead to loss in height, reduced rib cage mobility
and a decline in pulmonary function [28].
Adiposity has in previous studies been a significant predictor of
low levels of vitamin D in both COPD patients and subjects
without COPD [9,29]. As expected, we found that obesity was
negatively associated with levels of vitamin D and deficiency in
COPD patients. A suggested explanation for obesity-associated
vitamin D insufficiency, is a decreased bioavailability of 25(OH)D3
when deposited in body fat compartments [29].
Several studies have found an increased prevalence of vitamin D
deficiency in subjects with depression [30,31] or depressive
symptoms [32]. Patients with depression typically spend less time
outdoors and exhibit less physical activity. These factors are also
Table 2. Serum levels of 25(OH)D in ng/mL, mean6sd, for
different potential explanatory variables by subject category.
COPD p** Controls p**
25(OH)D, ng/mL 25.2610.0 25.069.5
Sex 0.58 0.42
Women 25.6610.4 25.569.4
Men 24.969.8 24.669.5
Age 0.10 ,0.001
40–54 22.5610.2 20.467.9
55–64 25.0610.4 27.669.4
.65 2669.4 28.369.0
Smoking habits ,0.01 ,0.01
Never 25.968.3
Ex 26.369.9 27.569.0
Current 23.669.9 23.469.7
BMI* (kg/m2) 0.001 0.22
,18.5 21.6610.0 28.460.0
18.5–24.9 26.0610.2 25.969.4
25–30 26.569.4 25.069.4
.30 21.669.7 22.6610.1
Comorbidity, Charlsons score 0.94 0.31
,2 25.1610.1 24.969.4
$2 25.169.9 27.0610.4
Depression, CES-D score$16 ,0.01
Yes 22.0610.3
No 26.069.9
Season ,0.001 ,0.001
Winter 20.969.8 22.068.9
Spring 22.769.6 23.769.4
Summer 27.869.4 32.067.3
Autumn 20.669.5 30.268.1
GOLD status: ,0.001
II (FEV1 50–80) 28.169.8
III (FEV1 30–50) 22.769.3
IV (FEV1 0–30) 21.6610.0
Hypoxaemia (resting
PaO2
1,8.0)
,0.01
Yes 20.568.1
No 25.9610.0
Not measured 24.0610.7
Cough with phlegm 0.22
Yes 24.6610.2
No 25.69.7
Dyspnea (grade III) 0.01
Yes 23.769.6
No 26.3610.1
Inhaled steroids, ICS 0.05
Yes 24.5610.1
No 26.569.5
Exacerbations#: 0.18
,2 last 12 months 25.469.9
$2 last 12 months 23.7610.5
Table 2. Cont.
COPD p** Controls p**
Treatment for osteoporosis 0.33
Yes 27.9610.9
No 25.0610.0
*BMI: body mass index.
#Exacerbations requiring either hospitalisation or treatment with oral
antibiotics or oral steroids.
1PaO2: arterial oxygen tension.
**Associations were tested with t-test and ANOVA.
doi:10.1371/journal.pone.0038934.t002
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Figure 2. Forced expiratory volume in 1 s (FEV1) plotted as a function of serum 25(OH)D levels for COPD patients and controls. The
Pearson coefficient (r) is calculated and given in the graph.
doi:10.1371/journal.pone.0038934.g002
Figure 1. Seasonal variation of measured serum 25(OH)D in controls and COPD patients.
doi:10.1371/journal.pone.0038934.g001
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associated with more severe COPD, and could confound a
relationship between vitamin D deficiency and COPD. In the
current study, the addition of depression to the multivariate
models did not change the increased risk of vitamin D deficiency
in COPD patients compared to controls, nor did it change the
observed relationship between vitamin D and FEV1.
However, our data showed a significant independent association
between depression and lower levels of vitamin D in COPD
patients. To our knowledge this has not been previously reported
in COPD patients. Whether this is caused by factors such as less
physical activity, less time spent outdoors and change in diet we
cannot say from the current study. Longitudinal studies, taking
these potential confounders into account, are necessary to address
this important issue.
Several studies demonstrate that vitamin D plays a role in
susceptibility to airway infections [5,6]. One explanation for this is
the already mentioned role of vitamin D in the innate immune
response, including its ability to induce the production of
antimicrobial peptides [23]. In Costa Rican children with asthma,
the number of hospitalizations following exacerbation showed an
Table 5. Coefficients from multiple linear regression and logistic regression models, showing the relationship between baseline
predictors and serum levels of 25(OH)D in COPD patients.
25(OH)D 25(OH)D ,20 ng/mL
Coef. CI p OR CI P
Smoking habits
Ex 0 1
Current 24.02 26.05, 21.99) ,0.001 3.15 (1.81, 5.47) ,0.001
BMI* (kg/m2) 20.37 20.57, 20.17) ,0.001 1.01 (1.02, 1.14) 0.005
,18.5 22.85 26.81, 1.11) 0.16 1.44 (0.52, 3.97) 0.48
18.5–24.9 0 1
25–30 21.52 23.77, 0.74) 0.19 1.08 (0.57, 2.05) 0.8
.30 26.63 29.54, 23.72) ,0.001 4.26 (1.97, 9.19) ,0.001
Season#
Winter 0 1
Spring 3.12 20.03, 6.26) 0.052 0.72 (0.33, 1.58) 0.42
Summer 6.99 (4.26, 9.73) ,0.001 0.22 (0.11, 0.46) ,0.001
Autumn 2.71 21.78, 7.19) 0.24 0.57 (0.19, 1.71) 0.31
GOLD status:
II (FEV1 50–80% predicted) 0 1
III (FEV1 30–50% predicted) 24.71 26.86, 22.56) ,0.001 3.19 (1.72, 5.91) ,0.001
IV (FEV1 0–30% predicted) 25.64 29.02, 22.25) 0.001 7.13 (2.88, 17.64) ,0.001
Depression, CES-D score$16
Yes 23.29 25.76, 20.81) 0.009 1.74 (0.92, 3.31) 0.089
No 0 1
*For both the linear and logistic regression models a backward stepwise procedure was used with the following variables included at start: Age, sex, GOLD status,
hypoxemia (resting PaO2,8), dyspnea (grade III), inhaled steroids, ICS (yes or no), *body mass index (BMI), comorbidity (Charlsons score ,2 or $2), total white blood
count, treatment for osteoporosis (yes or no), depression (CES-D score$16) and exacerbation frequency ($2 last year; yes or no).
#Season was defined as winter (December–March), spring (April–May), summer (June–September), and autumn (October–November).
doi:10.1371/journal.pone.0038934.t005
Table 3. Correlation analysis of continuous variables
associated with baseline concentrations of serum 25(OH)D.
COPD Controls
Pearson’s
r P
Pearson’s
r P
Age, years 0.073 0.130 0.375 ,0.001
FEV1 in percent predicted 0.271 ,0.001 0.000 0.995
Resting PaO2
1 0.152 0.003 0.045 0.428
Total white blood count 20.112 0.023 20.076 0.202
#BMI: Body mass index.
1PaO2: Arterial oxygen tension.
doi:10.1371/journal.pone.0038934.t003
Table 4. Regression coefficients for the relationship between
subject status and serum levels of 25(OH)D, adjusted for sex,
age, BMI, smoking, comorbidities and season.
25(OH)D{ 25(OH)D* (,20 ng/mL)
Coef. CI p OR CI p
Study category
Controls 0 1
COPD subjects 24.34 26.31,
22.37)
p,0.001 2.32 (1.43,
3.75)
p = 0.001
{Linear regression model.
*Logistic regression model.
doi:10.1371/journal.pone.0038934.t004
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inverse relationship with levels of 25(OH)D [7]. The NHANES III
study reported an inverse dose-response relationship between
levels of 25(OH)D and upper respiratory tract infection in
individuals with asthma, and a similar trend was seen for COPD
patients although not significant after adjustment [5]. In the
current study, we did not find an association with self-reported
exacerbation frequency in the previous 12 months and levels of
25(OH)D. It might be that our indicator variable for exacerbation
frequency was not precise enough for the outcome, or that the
number of COPD patients that had experienced$2 exacerbations
the last year was too low (9%). However, the results are in line with
a recent one-year follow-up study, where baseline vitamin D levels
failed to predict exacerbations rates in a patient sample from a
randomized controlled trial (RCT) on Azithromycin [11]. Also,
the first RCT on vitamin D supplements and subsequent COPD
exacerbations was recently published, failing to show a positive
effect of supplements [33]. It is worth noting that due to the small
patient sample of 182 patients in this RCT [33], a rather large
effect of vitamin D would be necessary in order to produce a
significant difference between the groups.
These three studies together imply either that the relationship
between vitamin D and COPD exacerbations is weaker or may be
more complicated than hypothesized. More and larger longitudi-
nal studies are needed to elucidate this issue.
The strength of the current study was its large sample size with a
large number of baseline data recorded and accurate measure-
ment of vitamin D levels using state-of-the-art methodology (LC-
MS/MS). However, there are some methodological issues to
consider. First, we must point out that this is a cross-sectional study
and therefore inference of cause and effect is not possible. Second,
although diet might be a minimal contributor to vitamin D status
[34], lack of data on dietary intake or use of vitamin D
preparations is a limitation of our study. It is rare in Norway to
take vitamin D supplements, and we find no reason to assume a
difference in use of supplements within our study population
compared to the general population. The prevalence of subjects
with detectable levels of 25(OH)D2 was low (,0.01%), which is
consistent with the fact that in Norway 25(OH)D3 is used almost
exclusively is used as fortification and supplements [16].
Third, there was a significant difference in age between COPD
patients and controls, where the COPD patients were on average 5
years older than the controls. Among the controls, lower age was
significantly associated with lower levels of vitamin D, whereas no
association was found between age and vitamin D levels among
the COPD patients. Thus, it was important to adjust for age in the
multivariate models, to avoid a false negative association between
COPD status and vitamin D deficiency, due to confounding by a
younger control group.
In conclusion, COPD patients had an increased risk for having
vitamin D deficiency, and the relationship between lung function
and systemic levels of vitamin D was almost linear even after
adjustment for a large number of known and potential confound-
ers. Future longitudinal studies are warranted to assess the
predictive effect of levels of vitamin D on decline in lung function,
risk for depression, exacerbation frequency, and changes in body
composition in patients with COPD.
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